Related Experiment Video

Updated: Mar 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Targeting CDK9: a promising therapeutic opportunity in prostate cancer

Muhammed H Rahaman, Malika Kumarasiri, Laychiluh B Mekonnen1

  • 1Centre for Drug Discovery and DevelopmentSansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.

Endocrine-Related Cancer
|September 2, 2016
PubMed

Insights

Cyclin-dependent kinase 9 (CDK9) inhibitors show promise for treating prostate cancer (PCa) by targeting androgen receptor (AR) and anti-apoptotic proteins, offering new hope against castrate-resistant PCa.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Prostate cancer (PCa) progression is driven by androgen receptor (AR) hyperactivity and anti-apoptotic proteins.
  • Traditional therapies targeting AR are becoming obsolete in castrate-resistant PCa due to AR reprogramming.
  • Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator implicated in PCa.

Purpose of the Study:

  • To review the biological functions of CDK9.
  • To explore CDK9's involvement with the androgen receptor (AR) in prostate cancer.
  • To evaluate the therapeutic potential of CDK9 inhibitors for advanced and castrate-resistant PCa.

Main Methods:

  • Literature review of CDK9's role in gene transcription.
  • Analysis of CDK9's interaction with androgen receptor signaling pathways.
  • Examination of preclinical and clinical data on CDK9 inhibitors in prostate cancer models.

Main Results:

  • CDK9 inhibition effectively suppresses AR activity and reduces anti-apoptotic protein expression.
  • CDK9 targeting offers a dual mechanism to combat castrate-resistant PCa.
  • CDK9 inhibitors demonstrate potential in overcoming therapeutic resistance.

Conclusions:

  • CDK9 is a promising therapeutic target for prostate cancer, particularly in advanced and castrate-resistant stages.
  • Targeting CDK9 presents a novel strategy to overcome resistance to traditional androgen receptor-targeted therapies.
  • Further investigation into CDK9 inhibitors could lead to improved treatment outcomes for PCa patients.
Keywords:
CDK9RNAPII transcriptionanti-apoptotic proteinsapoptosisprostate cancertherapeutics

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells08:03

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

Published on: October 20, 2015

14.7K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K